GMP Inspections Still A Risky Process For OTC Firms – Attorney
This article was originally published in The Pink Sheet Daily
Executive Summary
OTC manufacturers face heightened responsibility to maintain organized quality systems despite FDA’s new risk-based GMP initiative, attorney Bass contends. Agency inspections of OTC plants are increasingly rigorous and broader in scope, he says.